Business

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell

articleCelularity Inc.January 4, 20243/company/celularity-inc/news/celularity-confirms-commercialization-agreement-with-biocellgraft-for-the-manufacture-and-distribution-of-advanced-biomaterial-products-for-use-in-oral-healthcare
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

About this update from Celularity Inc.

[{"type":"text","content":"FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html. Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder of Celularity, said, “This commercialization agreement with BioCellgraft opens an important pathway for Celularity-manufactured, BioCellgraft-branded and marketed advanced biomaterial products into dental and oral healthcare applications in the United States that include periodontology, implant dentistry and oral surgery, all of which are large and growing markets.” Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include statements regarding The Company’s ability to sufficiently capitalize itself through cash flow from its manufactured biomaterial products, technical ope...

More updates from Celularity Inc.